New CEO at TxCell

TxCell SA, a biotechnology company developing personalised cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, has recently appointed Damian Marron as Chief Executive Officer (CEO) while former CEO and Chairman of the Board Francois Meyer becomes Executive Chairman of the Board of Directors. The business targets niche and orphan indications for which there are few or no treatment options and a high unmet medical need.

One of the main initial tasks for Damian as CEO will be to guide the development of Ovasave(R), the company’s lead autologous Ag-Treg cell-based immunotherapy. Ovasave is currently in phase II development for the treatment of Crohn’s disease in patients who are refractory to current treatments, which estimated to affect 160,000 such patients per year in Europe and in the US alone.

 “At this stage of TxCell’s development, it has been critical for us to appoint a CEO who has both a high level of experience at working in niche and orphan market places with unmet medical needs, as well as for both private and public companies,” said Francois Meyer, Executive Chairman of the TxCell Board. “As a result, the Board members and I feel that Damian’s 26 years’ biotechnology and pharmaceutical experience will make him invaluable to TxCell’s medium and long term development. Damian’s proven management skills allied to his range of experience including financing, corporate development, product and technology licensing, research and development and sales and marketing will be instrumental for our strategy of building a leading cell therapy company with innovative personalised treatments for chronic inflammatory and autoimmune diseases.”